Summary
Abstract
Ropivacaine (Naropin®) is the pure S(−)-enantiomer of propivacaine, and is a long-acting amide local anaesthetic agent, eliciting nerve block via reversible inhibition of sodium ion influx in nerve fibres.
Ropivacaine is a well tolerated regional anaesthetic effective for surgical anaesthesia as well as the relief of postoperative and labour pain. The efficacy of ropivacaine is similar to that of bupivacaine and levobupivacaine for peripheral nerve blocks and, although it may be slightly less potent than bupivacaine when administered epidurally or intrathecally, equi-effective doses have been established. Clinically adequate doses of ropivacaine appear to be associated with a lower incidence or grade of motor block than bupivacaine. Thus ropivacaine, with its efficacy, lower propensity for motor block and reduced potential for CNS toxicity and cardiotoxicity, appears to be an important option for regional anaesthesia and for the management of postoperative and labour pain.
Pharmacological Properties
Like other local anaesthetics, ropivacaine elicits nerve block via reversible inhibition of sodium ion influx in nerve fibres. The pKa of ropivacaine is similar to that of bupivacaine and levobupivacaine (≈8.2) but, unlike racemic bupivacaine, ropivacaine is the pure S(−)-enantiomer of propivacaine. It has lower lipid solubility and is less likely than bupivacaine to penetrate large, myelinated motor fibres. The degree of ropivacaine-induced sensory and motor block are dose- and age-dependent.
Despite the lower potency (based on minimum local anaesthetic concentrations) of ropivacaine than bupivacaine or levobupivacaine at lower doses, such as those used for epidural or intrathecal analgesia, ropivacaine has similar efficacy to these agents at higher doses such as those used for peripheral nerve block.
As with other local anaesthetics, ropivacaine has the potential to induce cardiovascular toxicity (e.g. arrhythmias and reduced myocardial conductivity and contractility) and CNS toxicity (e.g. seizures) at high plasma concentrations such as those occurring after large doses or inadvertent intravascular administration. It has a significantly higher threshold for cardiovascular and CNS toxicity than bupivacaine in animals and healthy volunteers.
Ropivacaine displays linear and dose-proportional pharmacokinetics up to 80mg (when administered intravenously). Absorption from the epidural space is complete and biphasic; the first phase (half-life [t;] 14 minutes) is followed by a slower second phase (t; 4.2 hours). Ropivacaine is extensively protein bound and crosses the placenta during epidural administration for Caesarean section. It is metabolised in the liver and excreted in the urine.
Therapeutic Efficacy
Randomised, double-blind, comparative clinical trials in adults have demonstrated the efficacy of ropivacaine in providing a profound sensory and motor block suitable for anaesthesia and a sensory/motor block profile suitable for postoperative or labour pain when administered by various routes (principally epidural or intrathecal administration and peripheral nerve block).
For epidurally administered surgical anaesthesia, ropivacaine and bupivacaine have similar efficacy, whereas with epidural administration for postoperative or labour analgesia, where doses required are lower than those needed for anaesthesia, ropivacaine has a shorter-lasting sensory block as well as a lower incidence/ degree of motor block than bupivacaine; equipotent doses have been established.
The duration of analgesia was less with ropivacaine than bupivacaine when administered intrathecally for anaesthesia or labour pain relief, but the duration of sensory block is still adequate for anaesthesia and the quicker regression of the motor block encourages mobilisation and recovery.
Peripheral nerve block for anaesthesia in orthopaedic surgery and for postoperative pain relief requires the use of relatively high doses of regional anaesthetic agents and the potency differences between ropivacaine and bupivacaine that were evident with epidural or intrathecal administration were not observed with this route of administration.
Ropivacaine and levobupivacaine are generally similarly effective for the above indications and routes of administration.
In children aged <12 years, ropivacaine provided effective postoperative pain relief when administered as a caudal or lumbar epidural injection, as a continuous epidural infusion or as a peripheral nerve block. The analgesic efficacy of ropivacaine was similar to that of bupivacaine and levobupivacaine; however, postoperative motor blockade was significantly less in ropivacaine than in bupivacaine recipients.
Tolerability
Ropivacaine is generally well tolerated regardless of the route of administration. Adverse events that occurred in ≥5% of patients in clinical trials who received ropivacaine 0.125–1% via various routes of administration for surgery, labour, Caesarean section, postoperative pain management, peripheral nerve block or local infiltration were hypotension (32%), nausea (17%), vomiting (7%), brady-cardia (6%) and headache (5%). Epidural administration of ropivacaine for surgery produced dose-dependent adverse events similar to those observed with equal doses of bupivacaine. Ropivacaine is generally well tolerated in the fetus or neonate following maternal epidural administration. The incidence of cardiovascular and CNS toxicity as a result of inadvertent intravascular injection of ropivacaine appears to be low.
The tolerability of ropivacaine in children (aged from 1 month to 15 years) appears to be at least similar to that of bupivacaine or levobupivacaine and is generally good, regardless of the route of administration. The most frequently occurring adverse events were nausea and vomiting.
Similar content being viewed by others
Notes
The use of trade names is for product identification purposes only and does not imply endorsement.
References
Hansen TG. Ropivacaine: a pharmacological review. Expert Rev Neurother 2004 Sep; 4(5): 781–91
McClellan KJ, Faulds D. Ropivacaine: an update of its use in regional anaesthesia. Drugs 2000 Nov; 60: 1065–93
AstraZeneca. Global Leaders in Anaesthesia; global prescribing information [online]. Available from URL: http://www.anaesthesia-az.com [Accessed 2005 Jul 18]
Rosenberg PH, Heinonen E. Differential sensitivity of A and C nerve fibres to long-acting amide local anaesthetics. Br J Anaesth 1983; 55: 163–7
Bader AM, Datta S, Flanagan H, et al. Comparison of bupivacaine- and ropivacaine-induced conduction blockade in the isolated rabbit vagus nerve. Anesth Analg 1989; 68: 724–7
Kindler CH, Paul M, Zou H, et al. Amide local anaesthetics potently inhibit the human tandem pore domain background K+ channel TASK-2 (KCNK5). J Pharmacol Exp Ther 2003; 306(1): 84–92
Polley LS, Columb MO, Naughton NN, et al. Relative analgesic potencies of levobupivacaine and ropivacaine for epidural analgesia in labor. Anesthesiology 2003 Dec; 99(6): 1354–8
Capogna G, Celleno D, Fusco P, et al. Relative potencies of bupivacaine and ropivacaine for analgesia in labour. Br J Anaesth 1999; 82(3): 371–3
Camorcia M, Capogna G, Columb MO. Minimum local analgesic doses of ropivacaine, levobupivacaine, and bupivacaine for intrathecal labor analgesia. Anesthesiology 2005 Mar; 102(3): 646–50
Lacassie HJ, Columb MO, Lacassie HP, et al. The relative motor blocking potencies of epidural bupivacaine and ropivacaine in labor. Anesth Analg 2002 Jul; 95: 204–8
Sia AT, Goy RW, Lim Y, et al. A comparison of median effective doses of intrathecal levobupivacaine and ropivacaine for labor analgesia. Anesthesiology 2005 Mar; 102(3): 651–6
Benhamou D, Ghosh C, Mercier FJ. A randomized sequential allocation study to determine the minimum effective analgesic concentration of levobupivacaine and ropivacaine in patients receiving epidural analgesia for labor. Anesthesiology 2003 Dec; 99(6): 1383–6
Camorcia M, Capogna G, Lyons G, et al. Epidural test dose with levobupivacaine and ropivacaine: determination of ED(50) motor block after spinal administration. Br J Anaesth 2004 Jun; 92(6): 850–3
Casati A, Fanelli G, Magistris L, et al. Minimum local anesthetic volume blocking the femoral nerve in 50% of cases: a double-blinded comparison between 0.5% ropivacaine and 0.5% bupivacaine. Anesth Analg 2001 Jan; 92: 205–8
Knudsen K, Beckman Suurkula M, Blomberg S, et al. Central nervous and cardiovascular effects of i.V. infusions of ropivacaine, bupivacaine and placebo in volunteers. Br J Anaesth 1997 May; 78(5): 507–14
Scott DB, Lee A, Fagan D, et al. Acute toxicity of ropivacaine compared with that of bupivacaine. Anesth Analg 1989; 69: 563–9
Stewart J, Kellett N, Castro D. The central nervous system and cardiovascular effects of levobupivacaine and ropivacaine in healthy volunteers. Anesth Analg 2003 Aug; 97(2): 412–6
Atanassoff PG, Hartmannsgruber MWB. Central nervous system side effects are less important after iv regional anesthesia with ropivacaine 0.2% compared to lidocaine 0.5% in volunteers. Can J Anesth 2002 Feb; 49: 169–72
Dory P, Dewinde P, Vanderick B, et al. The comparative toxicity of ropivacaine and bupivacaine at equipotent doses in rats. Anesth Analg 2000; 91: 1489–92
Ohmura S, Kawada M, Ohta T, et al. Systemic toxicity and resuscitation in bupivacaine-, levobupivacaine- or ropiva-caine-infused rats. Anesth Analg 2001; 93: 743–8
Zhang S, Yao S, Li Q. Effects of ropivacaine and bupivacaine on rabbit myocardial energetic metabolism and mitochondria oxidation. J Huazhong Univ Sci Technolog Med Sci 2003; 23(2): 178–9
Sztark F, Malgat M, Dabadie P, et al. Comparison of the effects of bupivacaine and ropivacaine on heart cell mitochondrial bioenergetics. Anesthesiology 1998; 88: 1340–9
Kawano T, Oshita S, Takahashi A, et al. Molecular mechanisms of the inhibitory effects of bupivacaine, levobupivacaine, and ropivacaine on sarcolemmal adenosine triphosphate-sensitive potassium channels in the cardiovascular system. Anesthesiology 2004 Aug; 101(2): 390–8
Paternoster DM, Micaglio M, Tambuscio, et al. The effects of epidural analgesia and uterine contractions on fetal oxygen saturation during the first stage of labour. Int J Obstet Anesth 2001 Apr; 10(2): 103–7
Lee BB, Kee WDN, Wong ELY, et al. Dose-response study of epidural ropivacaine for labor analgesia. Anesthesiology 2001 May; 94: 767–72
Zaric D. The effect of continuous lumbar epidural infusion of ropivacaine (0.1%, 0.2% and 0.3%) and 0.25% bupivacaine on sensory and motor block in volunteers. Reg Anesth 1996; 21(1): 14–25
Camorcia M, Capogna G, Lyons G, et al. The relative motor blocking potencies of intrathecal ropivacaine: effects of concentration. Anesth Analg 2004 Jun; 98(6): 1779–82
Simon MJG, Veering BT, Stienstra R, et al. The effects of age on neural blockade and hemodynamic changes after epidural anesthesia with ropivacaine. Anesth Analg 2002 May; 94: 1325–30
Deng XM, Xiao WJ, Tang GZ, et al. The minimum local anesthetic concentration of ropivacaine for caudal analgesia in children. Anesth Analg 2002 Jun; 94: 1465–8
Weber A, Fournier R, Riand N, et al. Duration of analgesia is similar when 15, 20, 25 and 30 mL of ropivacaine 0.5% are administered via a femoral catheter: Can J Anaesth 2005 Apr; 52 (4): 390–6
Graf BM, Zausig Y, Zink W. Current status and clinical relevance of studies of minimum local anaesthetic concentration (MLAC). Current Opinion in Anaesthesiology 2005; 18: 241–5
Berritta C, Camorcia M, Capogna G, et al. The relative motor blocking potencies of intrathecal bupivacaine, ropivacaine and levobupivacaine [abstract no. A584]. Eur J Anaesthesiol 2005; 22: 153
Aveline C, El Metaoua S, Masmoudi A, et al. The effect of clonidine on the minimum local analgesic concentration of epidural ropivacaine during labor. Anesth Analg 2002 Sep; 95: 735–40
Palm S, Gertzen W, Ledowski T, et al. Minimum local analgesic dose of plain ropivacaine vs. ropivacaine combined with sufentanil during epidural analgesia for labour. Anaesthesia 2001 Jun; 56: 526–9
Graf BM. The cardiotoxicity of local anesthetics: the place of ropivacaine. Curr Top Med Chem 2001 Aug; 1(3): 207–14
Graf BM, Abraham I, Eberbach N, et al. Differences in cardiotoxicity of bupivacaine and ropivacaine are the result of physicochemical and stereoselective properties. Anesthesiology 2002 Jun; 96(6): 1427–34
Santos A, DeArmas PI,.Systemic toxicity of levobupivacaine, bupivacaine and ropivacaine during continuous intravenous infusion to nonpregnant and pregnant ewes. Anesthesiology 2001; 95: 1256–64
Cederholm I, Evers H, Lofstrom JB, et al. Skin blood flow after intradermal injection of ropivacaine in various concentrations with and without epinephrine evaluated by laser doppler flowmetry. Reg Anesth 1992; 17: 322–8
Gonzalez T, Arias C, Caballero R, et al. Effects of levobupivacine, ropivacaine and bupivacaine on HERG channels: stereoselective bupivacaine block. Br J Pharmacol 2002; 137: 1269–79
Porter JM, Crowe B, Cahill M, et al. The effects of ropivacaine hydrochloride on platelet function: an assessment using the platelet function analyser (PFA-100). Anaesthesia 2001 Jan; 56: 15–8
Volk T, Schenk M, Voigt K, et al. Postoperative epidural anesthesia preserves lymphocyte, but not monocyte, immune function after major spine surgery. Anesth Analg 2004 Apr; 98(4): 1086–92
Mikawa K, Akamatsu H, Nishina K, et al. Effects of ropivacaine on human neutrophil function: comparison with bupivacaine and lidocaine. Eur J Anaesthesiol 2003 Feb; 20: 104–10
Batai I, Kerenyi M, Falvai J, et al. Bacterial growth in ropivacaine hydrochloride. Anesth Analg 2002 Mar; 94(3): 729–31
Kampe S, Poetter C, Buzello S, et al. Ropivacaine 0.1% with sufentanil 1 microg/mL inhibits in vitro growth of Pseudomonas aeruginosa and does not promote multiplication of Staphylococcus aureus. Anesth Analg 2003 Aug; 97(2): 409–11
Porter JM, Kelleher N, Flynn R, et al. Epidural ropivacaine hydrochloride during labour: protein binding, placental transfer and neonatal outcome. Anaesthesia 2001 May; 56: 418–23
Irestedt L, Emanuelsson BM, Ekblom A, et al. Ropivacaine 7.5 mg/ml for elective caesarean section: a clinical and pharmacokinetic comparison of 150 mg and 187.5 mg. Acta Anaesthesiol Scand 1997 Oct; 41(9): 1149–56
AstraZeneca. Naropin® (ropivacaine HCl) injection; prescribing information (USA) [online]. Available from URL: http://ww-w.astrazeneca-us.com [Accessed 2005 Nov 14]
Wank W, Buttner J, Rissler Maier K, et al. Pharmacokinetics and efficacy of 40 ml ropivacaine 7.5 mg/ml (300 mg), for axillary brachial plexus block: an open pilot study. Eur J Drug Metab Pharmacokinet 2002; 27(1): 53–9
Emanuelsson BM, Persson J, Alm C, et al. Systemic absorption and block after epidural injection of ropivacaine in healthy volunteers. Anesthesiology 1997 Dec; 87(6): 1309–17
Burm AG, Stienstra R, Brouwer RP, et al. Epidural infusion of ropivacaine for postoperative analgesia after major orthopedic surgery: pharmacokinetic evaluation. Anesthesiology 2000 Aug; 93(2): 395–403
Ala-Kokko TI, Alahuhta S, Jouppila P, et al. Feto-maternal distribution of ropivacaine and bupivacaine after epidural administration for cesarean section. Int J Obstet Anesth 1997 Jul; 6(3): 147–52
Leonard SA, Flynn R, Kelleher N, et al. Addition of epinephrine to epidural ropivacaine during labour: effects on onset and duration of action, efficacy, and systemic absorption of ropivacaine. Int J Obstet Anesth 2002 Jul; 11: 180–4
Ekstrom G, Gunnarsson UB. Ropivacaine, a new amide-type local anesthetic agent, is metabolized by cytochromes P450 1A and 3A in human liver microsomes. Drug Metab Dispos 1996 Sep; 24(9): 955–61
Halldin MM, Bredberg E, Angelin B, et al. Metabolism and excretion of ropivacaine in humans. Drug Metab Dispos 1996 Sep; 24(9): 962–8
Kopacz DJ, Emanuelsson BM, Thompson GE, et al. Pharmacokinetics of ropivacaine and bupivacaine for bilateral intercostal blockade in healthy male volunteers. Anesthesiology 1994 Nov; 81(5): 1139–48
Arvidsson T, Bruce HF, Halldin MM. Lack of metabolic racemisation of ropivacaine, determined by liquid chromatography using a chiral AGP column. Chirality 1995; 7(4): 272–7
Bosenberg AT, Thomas J, Lopez T, et al. Plasma concentrations of ropivacaine following a single-shot caudal block of 1, 2 and 3 mg/kg in children. Acta Anaesthesiol Scand 2001 Nov; 45: 1276–80
Karmakar MK, Aun CS, Wong EL. Ropivacaine undergoes slower systemic absorption from the caudal epidural space in children than bupivacaine. Anesth Analg 2002 Feb; 94(2): 259–65
Lonnqvist PA, Westrin P, Larsson BA, et al. Ropivacaine pharmacokinetics after caudal block in 1–8 year old children. Br J Anaesth 2000 Oct; 85: 506–11
Ala-Kokko TI, Partanen A, Karinen J, et al. Pharmacokinetics of 0.2% ropivacaine and 0.2% bupivacaine following caudal blocks in children. Acta Anaesthesiol Scand 2000 Oct; 44: 1099–102
Habre W, Bergesio R, Johnson C, et al. Pharmacokinetics of ropivacaine following caudal analgesia in children. Paediatr Anaesth 2000; 10(2): 143–7
McCann ME, Sethna NF, Mazoit JX, et al. The pharmacokinetics of epidural ropivacaine in infants and young children. Anesth Analg 2001 Oct; 93: 893–7
Hansen TG, Ilett KF, Lim SI, et al. Pharmacokinetics and clinical efficacy of long-term epidural ropivacaine infusion in children. Br J Anaesth 2000 Sep; 85: 347–53
Ala-Kokko TI, Karinen J, Raiha E, et al. Pharmacokinetics of 0.75% ropivacaine and 0.5% bupivacaine after ilioinguinal-iliohypogastric nerve block in children. Br J Anaesth 2002 Sep; 89(3): 438–41
Hansen TG, Ilett KF, Reid C, et al. Caudal ropivacaine in infants: population pharmacokinetics and plasma concentrations. Anesthesiology 2001 Apr; 94: 579–84
Van Obbergh LJ, Roelants FA, Veyckemans F, et al. In children, the addition of epinephrine modifies the pharmacokinetics of ropivacaine injected caudally. Can J Anesth 2003 Jun-2003 31; 50(6): 593–8
Jokinen MJ, Ahonen J, Neuvonen PJ, et al. The effect of erythromycin, fluvoxamine, and their combination on the pharmacokinetics of ropivacaine. Anesth Analg 2000 Nov; 91: 1207–12
Jokinen MJ, Olkkola KT, Ahonen J, et al. Effect of ciprofloxacin on the pharmacokinetics of ropivacaine. Eur J Clin Pharmacol 2003 Feb; 58: 653–7
Arlander E, Ekstrom G, Alm C, et al. Metabolism of ropivacaine in humans is mediated by CYP1A2 and to a minor extent by CYP3A4: an interaction study with fluvoxamine and ketoconazole as in vivo inhibitors. Clin Pharmacol Ther 1998 Nov; 64(5): 484–91
Jokinen MJ, Ahonen J, Neuvonen PJ, et al. Effect of clarithromycin and itraconazole on the pharmacokinetics of ropivacaine. Pharmacol Toxicol 2001 Apr; 88: 187–91
Jokinen MJ, Olkkola KT, Ahonen J, et al. Effect of rifampin and tobacco smoking on the pharmacokinetics of ropivacaine. Clin Pharmacol Ther 2001 Oct; 70: 344–50
Peduto VA, Baroncini S, Montanini S, et al. A prospective, randomized, double-blind comparison of epidural levobupivacaine 0.5% with epidural ropivacaine 0.75% for lower limb procedures. Eur J Anaesthesiol 2003 Dec; 20(12): 979–83
Bachmann-Mennenga B, Veit G, Biscoping J, et al. Epidural ropivacaine 1% with and without sufentanil addition for Caesarean section. Acta Anaesthesiol Scand 2005 Apr; 49(4): 525–31
Bachmann-Mennenga B, Veit G, Steinicke B, et al. Efficacy of sufentanil addition to ropivacaine epidural anaesthesia for Caesarean section. Acta Anaesthesiol Scand 2005 Apr; 49(4): 532–7
Crosby E, Sandier A, Finucane B, et al. Comparison of epidural anaesthesia with ropivacaine 0.5% and bupivacaine 0.5% for Caesarian section. Can J Anaesth 1998; 45(11): 1066–71
Bjornstad E, Smedvig JP, Bjerkreim T, et al. Epidural ropivacaine 7.5 mg/ml for elective Caesarean section: a double-blind comparison of efficacy and tolerability with bupivacaine. Acta Anaesthesiol Scand 1999; 43: 603–8
McGlade DP, Kalpoka MV, Mooney PH, et al. Comparison of 0.5% ropivacaine and 0.5% bupivacaine in lumbar epidural anaesthesia for lower limb orthopaedic surgery. Anaesth Intens Care 1997; 25: 262–6
Wolff AP, Hasselstrom L, Kerkamp HE, et al. Extradural ropivacaine and bupivacaine in hip surgery. Br J Anaesth 1995; 74: 458–60
Fettes PD, Hocking G, Peterson MK, et al. Comparison of plain and hyperbaric solutions of ropivacaine for spinal anaesthesia. Br J Anaesth 2005 Jan; 94(1): 107–11
Casati A, Moizo E, Marchetti C, et al. A prospective, randomized, double-blind comparison of unilateral spinal anesthesia with hyperbaric bupivacaine, ropivacaine, or levobupivacaine for inguinal herniorrhaphy. Anesth Analg 2004 Nov; 99(5): 1387–92
Whiteside JB, Burke D, Wildsmith JA. A comparison of 0.5% ropivacaine (5% glucose) with 0.5% bupivacaine (8% glucose) when used to provide spinal anaesthesia for elective surgery. Reg Anesth Pain Med 2001 Mar 30; 26 Suppl.: 69
Buckenmaier IIICC, Nielsen KC, Pietrobon R, et al. Small-dose intrathecal lidocaine versus ropivacaine for anorectal surgery in an ambulatory setting. Anesth Analg 2002 Nov; 95: 1253–7
Kallio H, Snail EV, Tuomas CA, et al. Comparison of hyperbaric and plain ropivacaine 15 mg in spinal anaesthesia for lower limb surgery. Br J Anaesth 2004 Nov; 93(5): 664–9
Kallio H, Snail E-VT, Kero MP, et al. A comparison of intrathecal plain solutions containing ropivacaine 20 or 15 mg versus bupivacaine 10 mg. Anesth Analg 2004 Sep; 99(3): 713–7
Gautier P, De Kock M, Huberty L, et al. Comparison of the effects of intrathecal ropivacaine, levobupivacaine, and bupivacaine for caesarean section. Br J Anaesth 2003 Nov; 91(5): 684–9
Khaw KS, Ngan Kee WD, Wong M, et al. Spinal ropivacaine for cesarean delivery: a comparison of hyperbaric and plain solutions. Anesth Analg 2002 Mar; 94(3): 680–5
Chung CJ, Choi SR, Yeo KH, et al. Hyperbaric spinal ropivacaine for cesarean delivery: a comparison to hyperbaric bupivacaine. Anesth Analg 2001 Jul; 93: 157–61
Danelli G, Fanelli G, Berti M, et al. Spinal ropivacaine or bupivacaine for cesarean delivery: a prospective, randomized, double-blind comparison. Reg Anesth Pain Med 2004 May-2004 30; 29(3): 221–6
Cappelleri G, Aldegheri G, Danelli G, et al. Spinal anesthesia with hyperbaric levobupivacaine and ropivacaine for outpatient knee arthroscopy: a prospective, randomized, double-blind study. Anesth Analg 2005 Jul; 101(1): 77–82
Gautier PE, de Kock MvSA,. Intrathecal ropivacaine for ambulatory surgery. A comparison between intrathecal bupivacaine and intrathecal ropivacaine for knee arthroscopy. Anesthesiology 1999; 91(5): 1239–45
Chung CJ, Yun SH, Hwang GB, et al. Intrathecal fentanyl added to hyperbaric ropivacaine for cesarean delivery. Reg Anesth Pain Med 2002 Nov-2002 31; 27: 600–3
De Kock M, Gautier P, Fanard L, et al. Intrathecal ropivacaine and clonidine for ambulatory knee arthroscopy: a dose-response study. Anesthesiology 2001 Apr; 94: 574–8
Hofmann-Kiefer K, Herbrich C, Seebauer A, et al. Ropivacaine 7.5 mg/ml versus bupivacaine 5 mg/ml for interscalene brachial plexus block: a comparative study. Anaesth Intensive Care 2002 Jun; 30: 331–7
Casati A, Borghi B, Fanelli G, et al. Interscalene brachial plexus anesthesia and analgesia for open shoulder surgery: a randomized, double-blinded comparison between levobupivacaine and ropivacaine. Anesth Analg 2003 Jan; 96: 253–9
Cline E, Franz D, Polley RD, et al. Analgesia and effectiveness of levobupivacaine compared with ropivacaine in patients undergoing an axillary brachial plexus block. AANA J 2004 Oct; 72(5): 339–45
Vaghadia H, Chan V, Ganapathy S, et al. A multicentre trial of ropivacaine 7.5 mg/ml(−l) vs bupivacaine 5 mg/ml (−) for supraclavicular brachial plexus anesthesia. Can J Anesth 1999; 46(10): 946–51
Raeder JC, Drosdahl S, Klaastad O, et al. Axillary brachial plexus block with ropivacaine 7.5 mg/mL: a comparative study with bupivacaine 5 mg/mL. Acta Anaesthesiol Scand 1999; 43(8): 794–8
Liisanantti O, Luukkonen J, Rosenberg PH. High-dose bupivacaine, levobupivacaine and ropivacaine in axillary brachial plexus block. Acta Anaesthesiol Scand 2004 May; 48(5): 601–6
Klein SM, Greengrass RA, Steele SM, et al. Comparison of 0.5% bupivacaine, 0.5% ropivacaine, and 0.75% ropivacaine for interscalene brachial plexus block. Anesth Analg 1998; 87: 1316–9
Bertini L, Tagariello V, Mancini S, et al. 0.75% and 0.5% ropivacaine for axillary brachial plexus block; a clinical comparison with 0.5% bupivacaine. Reg Anesth Pain Med 19999; 24 (6): 514–8
McGlade DP, Kalpokas MV, Mooney PH, et al. A comparison of 0.5% ropivacaine and 0.5% bupivacaine for axillary brachial plexus anaesthesia. Anaesth Intensive Care 1998; 26(5): 515–20
ElSaied AH, Steyn MP, Ansermino JM. Clonidine prolongs the effect of ropivacaine for axillary brachial plexus blockade. Can J Anesth 2000 Oct; 47: 962–7
Erlacher W, Schuschnig C, Koinig H, et al. Clonidine as adjuvant for mepivacaine, ropivacaine and bupivacaine in axillary, perivascular brachial plexus block. Can J Anesth 2001 Jun; 48: 522–5
Fanelli G, Casati A, Beccaria P, et al. A double-blind comparison of ropivacaine, bupivacaine, and mepivacaine during sciatic and femoral nerve blockade. Anesth Analg 1998; 87: 597–600
Casati A, Fanelli G, Borghi B, et al. Ropivacaine or 2% mepivacaine for lower limb peripheral nerve blocks. Anesthesiology 1999; 90(4): 1047–52
Casati A, Borghi B, Fanelli G, et al. A double-blinded, randomized comparison of either 0.5% levobupivacaine or 0.5% ropivacaine for sciatic nerve block. Anesth Analg 2002 Apr; 94(4): 987–90
Ernberg M, Kopp S. Ropivacaine for dental anesthesia: a dose-finding study. J Oral Maxillofac Surg 2002 Sep; 60: 1004–10
Kennedy M, Reader A, Beck M, et al. Anesthetic efficacy of ropivacaine in maxillary anterior infiltration. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2001 Apr; 91: 406–12
Huha T, Ala-Kokko TI, Salomaki T, et al. Clinical efficacy and pharmacokinetics of 1% ropivacaine and 0.75% bupivacaine in peribulbar anaesthesia for cataract surgery. Anaesthesia 1999; 54: 137–41
Corke PJ, Baker J, Cammack R. Comparison of 1 % ropivacaine and a mixture of 2% lignocaine and 0.5% bupivacaine for peribulbar anaesthesia in cataract surgery. Anaesth Intens Care 1999; 27: 249–52
Gillart T, Barrau P, Bazin JE, et al. Lidocaine plus ropivacaine versus lidocaine plus bupivacaine for peribulbar anaesthesia by single medial injection. Anaesth Analg 1999; 89: 1192–6
Woodward DK, Leung ATS, Tse MWI, et al. Peribulbar anaesthesia with 1% ropivacaine and hyaluronidase 300 IU ml−1: comparison with 0.5% bupivacaine/2% lidocaine and hyaluronidase 50 IU ml−1. Br J Anaesth 2000 Oct; 85: 618–20
Perello A, George J, Skelton V, et al. A double-blind randomised comparison of ropivacaine 0.5%, bupivacaine 0.375% — lidocaine 1% and ropivacaine 0.5% — lidocaine 1% mixtures for cataract surgery. Anaesthesia 2000 Oct; 55: 1003–7
Nociti JR, Mateus Serzedo PS, Zuccolotto EB, et al. Ropivacaine in peribulbar block: a comparative study with bupivacaine. Acta Anaesthesiol Scand 1999; 43: 799–802
McLure HA, Rubin AP, Westcott M, et al. A comparison of 1 % ropivacaine with a mixture of 0.75% bupivacaine and 2% lignocaine for peribulbar anaesthesia. Anaesthesia 1999; 54: 1178–82
Nicholson G, Sutton B, Hall GM. Ropivacaine for peribulbar anesthesia. Reg Anesth Pain Med 1999; 24(4): 337–40
Olmez G, Cakmak SS, Caca I, et al. Intraocular pressure and quality of blockade in peribulbar anesthesia using ropivacaine or lidocaine with adrenaline: a double-blind randomized study. Tohoku J Exp Med 2004 Nov; 204(3): 203–8
Brodner G, Mertes N, van Aken H, et al. Epidural analgesia with local anesthetics after abdominal surgery: earlier motor recovery with 0.2% ropivacaine than 0.175% bupivacaine. Anesth Analg 1998; 88: 128–33
Jayr C, Beaussier M, Gustafsson U, et al. Continuous epidural infusion of ropivacaine for postoperative analgesia after major abdominal surgery: comparative study with i.v. PCA morphine. Br J Anaesth 1998; 81: 887–92
Pouzeratte Y, Delay JM, Brunat G, et al. Patient-controlled epidural analgesia after abdominal surgery: ropivacaine versus bupivacaine. Anesth Analg 2001 Dec; 93: 1587–92
Scott DA, Blake D, Buckland M, et al. A comparison of epidural ropivacaine infusion alone and in combination with 1, 2 and 4mcg/ml fentanyl for seventy-two hours of postoperative analgesia after major abdominal surgery. Anesth Analg 1999; 88: 857–64
Senard M, Joris JL, Ledoux D, et al. A comparison of 0.1 % and 0.2% ropivacaine and bupivacaine combined with morphine for postoperative patient-controlled epidural analgesia after major abdominal surgery. Anesth Analg 2002 Aug; 95: 444–9
Wulf H, Biscoping J, Beland B, et al. Ropivacaine epidural anesthesia and analgesia versus general anesthesia and intravenous patient-controlled analgesia with morphine in the perioperative management of hip replacement. Anesth Analg 1999; 89: 111–9
Forster JG, Rosenberg PH. Small dose of clonidine mixed with low-dose ropivacaine and fentanyl for epidural analgesia after total knee arthroplasty. Br J Anaesth 2004 Nov; 93(5): 670–7
McClelland AM, Beckett N, Milligan KR. Post operative analgesia following total hip replacement surgery: a comparison of levobupivacaine and ropivacaine via epidural infusion [abstract no. S-344]. Anesth Analg 2002 Feb; 94
Dobrydnjov I, Axelsson K, Gupta A, et al. Improved analgesia with clonidine when added to local anesthetic during combined spinal-epidural anesthesia for hip arthroplasty: a double-blind, randomized and placebo-controlled study. Acta Anaesthesiol Scand 2005 Apr; 49(4): 538–45
Bertini L, Mancini S, Di Benedetto P, et al. Postoperative analgesia by combined continuous infusion and patient-controlled epidural analgesia (PCEA) following hip replacement: ropivacaine versus bupivacaine. Acta Anaesthesiol Scand 2001 Jul; 45: 782–5
Muldoon T, Milligan K, Quinn P, et al. Comparison between extradural infusion of ropivacaine or bupivacaine for the prevention of postoperative pain after total knee arthoplasty. Br J Anaesth 1998; 80: 680–1
Lorenzini C, Moreira LB, Ferreira MBC. Efficacy of ropivacaine compared with ropivacaine plus sufentanil for postoperative analgesia after major knee surgery. Anaesthesia 2002 May; 57: 424–8
Borgeat A, Kalberer F, Jacob H, et al. Patient-controlled interscalene analgesia with ropivacaine 0.2% versus bupivacaine 0.15% after major open shoulder surgery: the effects on hand motor function. Anesth Analg 2001 Jan; 92: 218–23
Borgeat A, Tewes E, Biasca N, et al. Patient-controlled interscalene analgesia with ropivacaine after major shoulder surgery: PCIA vs PCA. Br J Anaesth 1998; 81: 603–5
Eroglu A, Uzunlar H, Sener M, et al. A clinical comparison of equal concentration and volume of ropivacaine and bupivacaine for interscalene brachial plexus anesthesia and analgesia in shoulder surgery. Reg Anesth Pain Med 2004 Nov-2004 31; 29(6): 539–43
Casati A, Magistris L, Fanelli G, et al. Small-dose clonidine prolongs postoperative analgesia after sciatic-femoral nerve block with 0.75% ropivacaine for foot surgery. Anesth Analg 2000; 91: 388–92
Landau R, Schiffer E, Morales M, et al. The dose-sparing effect of clonidine added to ropivacaine for labor epidural analgesia. Anesth Analg 2002 Sep; 95: 728–34
Ilfeld BM, Morey TE, Thannikary LJ, et al. Clonidine added to a continuous interscalene ropivacaine perineural infusion to improve postoperative analgesia: a randomized, double-blind, controlled study. Anesth Analg 2005 Apr; 100(4): 1172–8
Ilfeld BM, Morey TE, Wright TW, et al. Continuous interscalene brachial plexus block for postoperative pain control at home: a randomized, double-blinded, placebo-controlled study. Anesth Analg 2003 Apr; 96(4): 1089–95
McNamee DA, Convery PN, Milligan KR. Total knee replacement: a comparison of ropivacaine and bupivacaine in combined femoral and sciatic block. Acta Anaesthesiol Scand 2001 Apr; 45: 477–81
Casati A, Vinciguerra F, Cappelleri G, et al. Levobupivacaine 0.2% or 0.125% for continuous sciatic nerve block: a prospective, randomized, double-blind comparison with 0.2% ropivacaine. Anesth Analg 2004 Sep; 99(3): 919–23
Johansson B, Hallerback B, Stubberod A, et al. Preoperative local infiltration with ropivacaine for postoperative pain relief after inguinal hernia repair. Eur J Surg 1997; 163: 371–8
Mulroy MF, Burgess FW, Emanuelsson B-M. Ropivacaine 0.25% and 0.5%, but not 0.125%, provide effective wound infiltration analgesia after outpatient hernia repair, but with sustained plasma drug levels. Reg Anesth Pain Med 1999; 24(2): 136–41
Pettersson N, Berggren P, Larsson M, et al. Pain relief by wound infiltration with bupivacaine or high-dose ropivacaine after inguinal hernia repair. Reg Anesth Pain Med 1999; 24(6): 569–75
Updike GM, Manolitsas TP, Cohn DE, et al. Pre-emptive analgesia in gynecologic surgical procedures: preoperative wound infiltration with ropivacaine in patients who undergo laparotomy through a midline vertical incision. Am J Obstet Gynecol 2003 Apr; 188: 901–5
Bisgaard T, Klarskov B, Kristiansen VB, et al. Multi-regional local anaesthetic infiltration during laparoscopic cholecystectomy in patients receiving multi-modal prophylactic analgesia: A randomised, double-blinded, placebo-controlled study. Anesth Analg 1999; 89(4): 1017–24
Papagiannopoulou P, Argiriadou H, Georgiou M, et al. Preincisional local infiltration of levobupivacaine vs ropivacaine for pain control after laparoscopic cholecystectomy. Surg Endosc 2003 Dec; 17(12): 1961–4
Callesen T, Hjort D, Mogensen T, et al. Combined field block and i.p. instillation of ropivacaine for pain management after laparoscopic sterilisation. Br J Anaesth 1999; 82(4): 586–90
Apostolopoulos K, Labropoulou E, Samaan R, et al. Ropivacaine compared to lidocaine for tonsillectomy under local anaesthesia. Eur Arch Otorhinolaryngol 2003 Aug; 260(7): 355–7
Fredman B, Shapiro A, Zohar E, et al. The analgesic efficacy of patient-controlled ropivacaine instillation after cesarean delivery. Anesth Analg 2000 Dec; 91: 1436–40
Johansson A, Axelson J, Ingvar C, et al. Preoperative ropivacaine infiltration in breast surgery. Acta Anaesthesiol Scand 2000 Oct; 44: 1093–8
Horn EP, Schroeder F, Wilhelm S, et al. Wound infiltration and drain lavage with ropivacaine after major shoulder surgery. Anaesth Analg 1999; 89: 1461–6
Gottschalk A, Burmeister MA, Radtke P, et al. Continuous wound infiltration with ropivacaine reduces pain and analgesic requirement after shoulder surgery. Anesth Analg 2003 Oct; 97(4): 1086–91
Vinson-Bonnet B, Coltat JC, Fingerhut A, et al. Local infiltration with ropivacaine improves immediate postoperative pain control after hemorrhoidal surgery. Dis Colon Rectum 2002 Jan; 45: 104–8
Axelsson K, Nordenson U, Johanzon E, et al. Patient-controlled regional analgesia (PCRA) with ropivacaine after arthroscopic subacromial decompression. Acta Anaesthesiol Scand 2003 Sep; 47(8): 993–1000
Kakagia D, Fotiadis S, Tripsiannis G. Comparative efficacy of ropivacaine and bupivacaine infiltrative analgesia in otoplasty. Ann Plast Surg 2005 Apr; 54(4): 409–11
Marret E, Gentili M, Bonnet MP, et al. Intra-articular ropivacaine 0.75% and bupivacaine 0.50% for analgesia after arthroscopic knee surgery: a randomized prospective study. Arthroscopy 2005 Mar; 21(3): 313–6
Franceschi F, Rizzello G, Cataldo R, et al. Comparison of morphine and ropivacaine following knee arthroscopy. Arthroscopy 2001 May-2001 30; 17: 477–80
Bosenberg A, Thomas J, Lopez T, et al. The efficacy of caudal ropivacaine 1, 2 and 3 mg/ml for postoperative analgesia in children. Paediatr Anaesth 2002 Jan; 12: 53–8
Astuto M, Disma N, Arena C. Levobupivacaine 0.25% compared with ropivacaine 0.25% by the caudal route in children. Eur J Anaesthesiol 2003 Oct; 20(10): 826–30
Da Conceicao MJ, Coelho L. Caudal anaesthesia with 0.375% ropivacaine or 0.375% bupivacaine in paediatric patients. Br J Anaesth 1998 Apr; 80(4): 507–8
Da Conceicao MJ, Coelho L, Khalil M. Ropivacaine 0.25% compared with bupivacaine 0.25% by the caudal route. Paediatr Anaesth 1999; 9(3): 229–33
Ivani G, DE Negri P, Lonnqvist PA, et al. Caudal anesthesia for minor pediatric surgery: a prospective randomized comparison of ropivacaine 0.2% vs levobupivacaine 0.2%. Paediatr Anaesth 2005 Jun; 15(6): 491–4
Ivani G, Lampugnani E, Torre M, et al. Comparison of ropivacaine with bupivacaine for paediatric caudal block. Br J Anaesth 1998 Aug; 81(2): 247–8
Khalil S, Campos C, Farag AM, et al. Caudal block in children: ropivacaine compared with bupivacaine. Anesthesiology 1999 Nov; 91(5): 1279–84
Locatelli B, Ingelmo P, Sonzogni V, et al. Randomized, double-blind, phase III, controlled trial comparing levobupivacaine 0.25%, ropivacaine 0.25% and bupivacaine 0.25% by the caudal route in children. Br J Anaesth 2005 Mar; 94(3): 366–71
Lee HM, Sanders GM. Caudal ropivacaine and ketamine for postoperative analgesia in children. Anaesthesia 2000 Aug; 55(8): 806–10
Gunes Y, Secen M, Ozcengiz D, et al. Comparison of caudal ropivacaine, ropivacaine plus ketamine and ropivacaine plus tramadol administration for postoperative analgesia in children. Paediatr Anaesth 2004 Jul; 14(7): 557–63
Ivani G, Lampugnani E, De Negri P, et al. Ropivacaine vs bupivacaine in major surgery in infants. Can J Anaesth 1999 May; 46 (5 Pt 1): 467–9
Thornton KL, Sacks MD, Hall R, et al. Comparison of 0.2% ropivacaine and 0.25% bupivacaine for axillary brachial plexus blocks in paediatric hand surgery. Paediatr Anaesth 2003 Jun; 13(5): 409–12
Giannoni C, White S, Enneking FK, et al. Ropivacaine with or without clonidine improves pediatric tonsillectomy pain. Otolaryngol Head Neck Surg 2001 Oct; 127: 1265–70
Park AH, Pappas AL, Fluder E, et al. Effect of perioperative administration of ropivacaine with epinephrine on postoperative pediatric adenotonsillectomy recovery. Arch Otolaryngol Head Neck Surg 2004 Apr; 130(4): 459–64
Antok E, Bordet F, Duflo F, et al. Patient-controlled epidural analgesia versus continuous epidural infusion with ropivacaine for postoperative analgesia in children. Anesth Analg 2003 Dec; 97(6): 1608–11
De Negri P, Ivani G, Tirri T, et al. A comparison of epidural bupivacaine, levobupivacaine, and ropivacaine on postoperative analgesia and motor blockade. Anesth Analg 2004 Jul; 99(1): 45–8
Halpern SH, Breen TW, Campbell DC, et al. A multicenter, randomized, controlled trial comparing bupivacaine with ropivacaine for labor analgesia. Anesthesiology 2003 Jun; 98: 1431–5
Lee BB, Ngan Kee WD, Ng FF, et al. Epidural infusions of ropivacaine and bupivacaine for labor analgesia: a randomized, double-blind study of obstetric outcome. Anesth Analg 2004 Apr; 98(4): 1145–52
Lim Y, Ocampo CE, Sia AT. A comparison of duration of analgesia of intrathecal 2.5 mg of bupivacaine, ropivacaine, and levobupivacaine in combined spinal epidural analgesia for patients in labor. Anesth Analg 2004 Jan; 98(1): 235–9
Benhamou D, Hamza J, Eledam J-J, et al. Continuous extradural infusion of ropivacaine 2mg ml-1 for pain relief during labour. Br J Anaesth 1997; 78: 748–50
Beilin Y, Galea M, Zahn J, et al. Epidural ropivacaine for the inititation of labor epidural analgesia: a dose finding study. Anesth Analg 1999; 88: 1340–50
Cascio MG, Gaiser RR, Camann WR, et al. Comparative evaluation of four different infusion rates of ropivacaine (2mg/mL) for epidural labour analgesia. 1998; 23(6): 548–53
Atienzar MC, Palanca JM, Borras R, et al. Ropivacaine 0.1% with fentanyl 2 microg mL(−l) by epidural infusion for labour analgesia. Eur J Anaesthesiol 2004 Oct; 21(10): 770–5
Lee BB, Ngan Kee WD, Lau WM, et al. Epidural infusions for labor analgesia: a comparison of 0.2% ropivacaine, 0.1% ropivacaine, and 0.1% ropivacaine with fentanyl. Reg Anesth Pain Med 2002 Jan 28; 27: 31–6
Ledin Eriksson S, Gentele C, Olofsson CH. PCEA compared to continuous epidural infusion in an ultra-low-dose regimen for labor pain relief: a randomized study. Acta Anaesthesiol Scand 2003 Oct; 47(9): 1085–90
Bremerich DH, Waibel HJ, Mierdl S, et al. Comparison of continuous background infusion plus demand dose and demand-only parturient-controlled epidural analgesia (PCEA) using ropivacaine combined with sufentanil for labor and delivery. Int J Obstet Anesth 2005 Apr; 14(2): 114–20
Supandji M, Sia AT, Ocampo CE. 0.2% Ropivacaine and levobupivacaine provide equally effective epidural labour analgesia. Can J Anaesth 2004 Nov; 51(9): 918–22
Purdie NL, McGrady EM. Comparison of patient-controlled epidural bolus administration of 0.1% ropivacaine and 0.1% levobupivacaine, both with 0.0002% fentanyl, for analgesia during labour. Anaesthesia 2004 Feb; 59(2): 133–7
Camorcia M, Capogna G. Epidural levobupivacaine, ropivacaine and bupivacaine in combination with sufentanil in early labour: a randomized trial. Eur J Anaesthesiol 2003 Aug; 20 (No. 8): 636–9
Gogarten W, Van de Velde M, Soetens E, et al. A multicentre trial comparing different concentrations of ropivacaine plus sufentanil with bupivacaine plus sufentanil for patient-controlled epidural analgesia in labour. Eur J Anaesthesiol 2004 Jan; 21(1): 38–45
Fischer C, Blanie P, Jaouen E, et al. Ropivacaine, 0.1% plus sufentanil, 0.5 mcg/ml, versus bupivacaine, 0.1% plus sufentanil, 0.5 mcg/ml, using patient-controlled epidural analgesia for labour. Anesthesiology 2000; 92(6): 1588–93
Evron S, Glezerman M, Sadan O, et al. Patient-controlled epidural analgesia for labor pain: effect on labor, delivery and neonatal outcome of 0.125% bupivacaine vs 0.2% ropivacaine. Int J Obstet Anesth 2004 Jan; 13(1): 5–10
Dresner M, Freeman J, Calow C, et al. Ropivacaine 0.2% versus bupivacaine 0.1 % with fentanyl: a double blind comparison for analgesia during labour. Br J Anaesth 2000 Dec; 85: 826–9
Levin A, Datta S, Camann WR. Intrathecal ropivacaine for labor anagesia: a comparison with bupivacaine. Anesth Analg 1998; 87: 624–7
Soni AK, Miller CG, Pratt SD, et al. Low dose intrathecal ropivacaine with or without sufentanil provides effective analgesia and does not impair motor strength during labour: a pilot study. Can J Anesth 2001 Jul 31; 48: 677–80
Hughes D, Hill D, Fee JPH. Intrathecal ropivacaine or bupivacaine with fentanyl for labour. Br J Anaesth 2001 Nov; 87: 733–7
Zink W, Graf BM. Benefit-risk assessment of ropivacaine in the management of postoperative pain. Drug Saf 2004; 27(14): 1093–114
Selander D, Sjovall J, Waldenlind L, et al. Accidental i.v. injections of ropivacaine: clinical experience of six cases [abstract]. Reg Anaesth 1997; 22(2S): 70
Klein SM, Pierce T, Rubin Y, et al. Successful rescuscitation after ropivacaine-induced ventricular fibrillation. Anesth Analg 2003; 97: 901–3
Writer WD, Stienstra R, Eddleston JM, et al. Neonatal outcomes and mode of delivery after epidural analgesia with ropivacaine and bupivacaine: a prospective meta-analysis. Br J Anaesth 1998; 81: 713–7
Wang RD, Dangler LA, Greengrass RA, et al. Update on ropivacaine. Expert Opinion on Pharmacotherapy 2001; 2(12): 2051–63
Casati A, Putzu M. Bupivacaine, levobupivacaine and ropivacaine: are they clinically different? Best Pract Res Clin Anaesthesiol 2005 Jun; 19(2): 247–68
Kuczkowski KM. Levobupivacaine and ropivacaine: the new choices for labor analgesia. Int J Clin Pract 2004 Jun; 58(6): 604–5
Capogna G. Ropivacaine and bupivacaine in obstetric analgesia. Eur J Anaesthesiol 2002 Apr; 19(4): 237–9
Stienstra R. The place of ropivacaine in anesthesia. Acta Anaesthesiol Belg 2003; 54(2): 141–8
Lew E, Vloka JD, Hadzic A. Ropivacaine for peripheral nerve blocks: Are there advantages? Techniques in Regional Anesthesia & Pain Management 2001; 5(2): 56–9
Ilfield BM, Kayser Enneking F. Continuous peripheral nerve blocks at home: a review. Anesth Analg 2005; 100: 1822–33
Polley LS, Columb MO. Ropivacaine and bupivacaine: concentrating on dosing! Anesth Analg 2003 May; 96: 1251–3
Merson N. A comparison of motor block between ropivacaine and bupivacaine for continuous labor epidural analgesia. AANA J 2001 Feb; 69(1): 54–8
AstraZeneca. Naropin (ropivacaine HCl): product monograph. Södertälje, Sweden: AstraZeneca Anaesthesia Group, 2004 Sep
Acknowledgements
At the request of the journal, AstraZeneca provided a non-binding review of this article.
Author information
Authors and Affiliations
Corresponding author
Additional information
Various sections of the manuscript reviewed by: M. Camorcia, Department of Anesthesia and Intensive Care, Città di Roma Hospital, Rome, Italy; A. Casati, Department of Anesthesia and Pain Therapy, Ospedale Maggiore de Parma, University of Parma, Parma, Italy; R. Gristwood, Cambridge BioConsultants Ltd., Cambridge, England; Y. Lim, Department of Women’s Anaesthesia, Division of Obstetrics and Gynaecology, KK Women’s and Children’s Hospital, Singapore; B. Papaziogas, Department of Surgery, 2nd Surgical Clinic of the Aristotle University of Thessaloniki/Greece, Thessaloniki, Greece; D.J. Pavlin, Department of Anesthesiology, University of Washington School of Medicine, Seattle, Washington, USA; M.A.E. Ramsay, Department of Anesthesiology and Pain Management, Baylor University Medical Center, Dallas, Texas, USA; G. Shorten, Department of Anaesthesia and Intensive Care Medicine, Cork University Hospital, Cork, Ireland; A.T. Sia, Department of Women’s Anaesthesia, Division of Obstetrics and Gynaecology, KK Women’s and Children’s Hospital, Singapore; M.J.G. Simon, Department of Anaesthesiology, Leiden University Medical Centre, Leiden, The Netherlands.
Data Selection
Sources: Medical literature published in any language since 1980 on ‘ropivacaine’, identified using MEDLINE and EMBASE, supplemented by AdisBase (a proprietary database of Adis International). Additional references were identified from the reference lists of published articles. Bibliographical information, including contributory unpublished data, was also requested from the company developing the drug.
Search strategy: MEDLINE search terms were ‘ropivacaine’. EMBASE search terms were ‘ropivacaine’. AdisBase search terms were ‘ropivacaine’ or ‘LEA-103’. Searches were last updated 1 November 2005.
Selection: Studies in patients who were in labour, undergoing surgery or had undergone surgery who received ropivacaine. Inclusion of studies was based mainly on the methods section of the trials. When available, large, well controlled trials with appropriate statistical methodology were preferred. Relevant pharmacodynamic and pharmacokinetic data are also included.
Index terms: Ropivacaine, anaesthesia, regional anaesthesia, local anaesthesia, post-operative pain, analgesia, pharmacodynamics, pharmacokinetics, therapeutic use, tolerability.
Rights and permissions
About this article
Cite this article
Simpson, D., Curran, M.P., Oldfield, V. et al. Ropivacaine. Drugs 65, 2675–2717 (2005). https://doi.org/10.2165/00003495-200565180-00013
Published:
Issue Date:
DOI: https://doi.org/10.2165/00003495-200565180-00013